Keratoprotection treatment after excimerlaser vision correction

Observational study of patients after excimerlaser vision correction by LASEK method.

Purpose: to estimate efficacy HILOZAR-COMOD® solution in patients after excimerlaser vision correction.

Patients and methods: We examined 80 eyes (40 patients) after excimer laser correction by LASIK method. All patients were divided in 2 groups. The patients from the first group were treated with by standard drug’s scheme, included deprotein izing the dialysate from the blood of healthy dairy calves (Solkoseryl® eye gel). HILOZAR-COMOD ® was prescribed as cornea protector in the 2 group of patients.

Results: In the first group complete cornea epitalization by biomicroscopy in 70 % eyes after 48 hours of excimerlaser vision correction was found. Minimal unepitalization areas were diagnosed in 30 % (12 eyes). In the second group complete cornea epitalization was found in 82,5 % eyes (33 eyes) in the same term after excimerlaser correction. Cornea epitelium defects in optical area were diagnosed in the17,5 % eyes. The difference between number of patients with cornea epitelium defects first and second groups was 12,5 %. 97,5 % patients (39 eyes) of second group (HILOZAR-COMOD ®) had complete cornea epitelization after 72 hours of excimer laser correction. In the same term unepitelization areas were found in 3 eyes (7,5 %) in patients of first group. It was to 5 % more than in the first group, where dexpantenol and hyaluronic acid was used (complete cornea epitalization in first group was found in 37 eyes).

Conclusions: The combined medicine included dexpantenol and hyaluronic acid decreases intensity of the dry eye symptoms, stimulate quick and full cornea healing and decrease the risk of postoperative complications risk.

1. Balashevich L. I. [Surgically correction refraction and accommodation anomalies]. Khirurgicheskaya korrektsiya anomaliy refraktsii i akkomodatsii. St. Petersburg, Chelovek, 2009 (in Russ.).

2. Lee HK, Lee KS, Kim HC, Lee SH, Kim EK. Nerve growth factor concentration and implications in photorefractive keratectomy vs laser in situ keratomileusis. Am. J. Ophthalmol. 2005;139:965‑971.

3. Nejima R, Miyata K, Tanabe T, Okamoto F, Hiraoka T, Kiuchi T, Oshika T. Corneal barrier function, tear film stability, and corneal sensation after photorefractive keratectomy and laser in situ keratomileusis. Am. J. Ophthalmol. 2005,139:64‑71

4. Egorov E. A., Alekseev V. N., Astakhov Yu. S. [Rational pharmacotherapy in ophthalmology]. Ratsional’naya farmakoterapiya v oftal’mologii. 2‑e izdanie. M.: Litterra, 2011. (in Russ.).

5. Way WA, Matsumoto S, Apel LJ, Wiese A, Tarlo K, Vehige J. Purite™ as a non-disruptive preservative for lubricating eye drop solutions in comparison to alternative preservatives. Invest. Ophthalmol. Vis. Sci. 2001;42 (4).

6. Maychuk Yu. F., Yani E. V. [Clinical evaluation of products based on hyaluronic acid]. Klinicheskaya otsenka preparatov na osnove gialuronovoy kisloty. [Refractive surgery and ophthalmology]. Refraktsionnaya khirurgiya i oftal’mologiya. 2008;8 (4): 35‑42. (in Russ.).

7. ХИЛОЗАР-КОМОД ®. Инструкция по применению

8. Egorov E. A. [Hyaluronic acid: application in ophthalmology and therapy of the syndrome of «dry eye»]. Gialuronovaya kislota: primenenie v oftal’mologii i terapii sindroma «sukhogo glaza». [Clinical Ophthalmology]. Klinicheskaya oftal’mologiya 2013; (2):71‑74. (in Russ.).

9. Hargittai I., Hargittai M. Molecular structure of hyaluronan; an introduction. Struct. Chem. 2008;19: 697‑717.

10. Scott J. E. Extracellular matrix, supramolecular organisation and shape. J. Anat. 1995; 187 (Pt 2):259‑269.

11. Lapcik L. Jr., Lapcik L., DeSmedt S. et al. Hyaluronan: preparation, structure, properties and applications. Chem. Rev. 1998; 98: 2663‑2684.

12. Gomes J. A., Amankwah R., Powell-Richards A. et al. Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br. J. Ophthalmol. 2004; 88:821‑825.

13. Brignole F., Pisella P.‑J., Dupas B. et al. Efficacy and satefy of 0,18 % sodium yaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefe’s Arch. Clin. Ophthalmol. 2005; 243:531‑538.

14. Johnson M. E., Murphy P. J., Boulton M. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefe’s Arch. Clin. Exp. Ophthalmol. 2006; 244:109‑112.

15. Prabhasawat P., Tesavibul N., Kasetsuwan N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br. J. Ophthalmol. 2007; 91:47‑50.

16. Schrage, N. F.; Frentz, M.; Reim, M. Changing the composition of buffered eye drops prevents undesired side effects. Br. J. Ophthalmol 2010; 94 (11):1519.